SLC5A2 and diabetes mellitus: The protocol for a three-way crossover study including a DPP4 inhibitor, thiazolidinedione and a SGLT2 inhibitor has been described, which will provide further information on stratification of glucose response to three diabetes medications by routine clinical features ascertained at baseline (25).